Therapeutic strategies to target RAS-mutant cancers

@article{Ryan2018TherapeuticST,
  title={Therapeutic strategies to target RAS-mutant cancers},
  author={Meagan B. Ryan and R. Corcoran},
  journal={Nature Reviews Clinical Oncology},
  year={2018},
  volume={15},
  pages={709-720}
}
RAS genes are the most commonly mutated oncogenes in cancer, but effective therapeutic strategies to target RAS-mutant cancers have proved elusive. A key aspect of this challenge is the fact that direct inhibition of RAS proteins has proved difficult, leading researchers to test numerous alternative strategies aimed at exploiting RAS-related vulnerabilities or targeting RAS effectors. In the past few years, we have witnessed renewed efforts to target RAS directly, with several promising… Expand
58 Citations
Direct targeting of oncogenic RAS mutants with a tumor-specific cytosol-penetrating antibody inhibits RAS mutant–driven tumor growth
  • 9
  • PDF
Targeting KRAS: The Elephant in the Room of Epithelial Cancers
Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition
  • 32
  • PDF
Targeting Alterations in the RAF-MEK Pathway.
  • 61
  • PDF
A Historic Perspective and Overview of H-Ras Structure, Oncogenicity, and Targeting
  • 1
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 203 REFERENCES
Targeting RAS-mutant cancers: is ERK the key?
  • 68
RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?
  • J. Downward
  • Biology, Medicine
  • Clinical Cancer Research
  • 2015
  • 114
  • PDF
The RAS-Effector Interaction as a Drug Target.
  • 34
  • PDF
Metabolic Dependencies in RAS-Driven Cancers
  • 133
  • PDF
...
1
2
3
4
5
...